Aisling Capital Management
Latest statistics and disclosures from Aisling Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BBIO, VRNA, SNDX, GLUE, PSTX, and represent 89.45% of Aisling Capital Management's stock portfolio.
- Added to shares of these 2 stocks: Onkure Therapeutics Inc-a, MRKR.
- Started 1 new stock position in Onkure Therapeutics Inc-a.
- Reduced shares in these 2 stocks: TECX, RPHM.
- Sold out of its positions in RPHM, TECX.
- Aisling Capital Management was a net seller of stock by $-3.3M.
- Aisling Capital Management has $282M in assets under management (AUM), dropping by 7.95%.
- Central Index Key (CIK): 0001766721
Tip: Access up to 7 years of quarterly data
Positions held by Aisling Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 15 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 59.1 | $167M | 6.1M | 27.44 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 18.4 | $52M | 1.1M | 46.44 |
|
|
| Syndax Pharmaceuticals (SNDX) | 4.8 | $14M | 1.0M | 13.22 |
|
|
| Monte Rosa Therapeutics (GLUE) | 3.6 | $10M | 1.5M | 6.94 |
|
|
| Poseida Therapeutics I (PSTX) | 3.6 | $10M | 1.0M | 9.60 |
|
|
| Bicara Therapeutics (BCAX) | 3.5 | $9.9M | 569k | 17.42 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 2.4 | $6.8M | 2.5M | 2.66 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 1.3 | $3.6M | 965k | 3.78 |
|
|
| Biomea Fusion (BMEA) | 1.1 | $3.1M | 799k | 3.88 |
|
|
| CalciMedica Com New (CALC) | 0.7 | $1.8M | 521k | 3.54 |
|
|
| Elevation Oncology (ELEV) | 0.6 | $1.6M | 2.8M | 0.56 |
|
|
| Aclaris Therapeutics (ACRS) | 0.4 | $1.1M | 435k | 2.48 |
|
|
| Marker Therapeutics Com New (MRKR) | 0.4 | $1.0M | +3% | 325k | 3.11 |
|
| OnKure Therapeutics Com Cl A | 0.3 | $762k | NEW | 89k | 8.60 |
|
| Viracta Therapeutics (VIRX) | 0.0 | $46k | 289k | 0.16 |
|
Past Filings by Aisling Capital Management
SEC 13F filings are viewable for Aisling Capital Management going back to 2018
- Aisling Capital Management 2024 Q4 filed Feb. 12, 2025
- Aisling Capital Management 2024 Q3 filed Nov. 13, 2024
- Aisling Capital Management 2024 Q2 filed Aug. 8, 2024
- Aisling Capital Management 2024 Q1 filed May 14, 2024
- Aisling Capital Management 2023 Q4 filed Feb. 7, 2024
- Aisling Capital Management 2023 Q3 filed Nov. 13, 2023
- Aisling Capital Management 2023 Q2 filed Aug. 11, 2023
- Aisling Capital Management 2023 Q1 filed May 9, 2023
- Aisling Capital Management 2022 Q4 filed Feb. 9, 2023
- Aisling Capital Management 2022 Q3 filed Nov. 3, 2022
- Aisling Capital Management 2022 Q2 filed Aug. 10, 2022
- Aisling Capital Management 2022 Q1 filed May 10, 2022
- Aisling Capital Management 2021 Q4 filed Feb. 18, 2022
- Aisling Capital Management 2021 Q3 filed Nov. 12, 2021
- Aisling Capital Management 2021 Q2 filed Aug. 6, 2021
- Aisling Capital Management 2021 Q1 filed May 14, 2021